Activated expression of the chemokine Mig after chemotherapy contributes to chemotherapy-induced bone marrow suppression and lethal toxicity

Blood

Volumn 119, Issue 21, 2012, Pages 4868-4877

  Lu, Huili ^a,b   Zhu, Shunying ^c   Qian, Lan ^a   Xiang, Di ^a   Zhang, Wu ^a   Nie, Aifang ^a   Gao, Jin ^a   Wu, Mingyuan ^a   Gao, Jinming ^d   Lu, Bao ^e   Yu, Yan ^c   Han, Wei ^a   Moldenhauer, Anja ^b,f  

^a SHANGHAI JIAO TONG UNIVERSITY   (China)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c SJTU Cornell Institute of Sustainable Agriculture and Biotechnology   (China)

^d PEKING UNION MEDICAL COLLEGE HOSPITAL   (China)

^e HARVARD MEDICAL SCHOOL   (United States)

^f KLINIKUM LUDWIGSHAFEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CD34 ANTIGEN; CHEMOKINE RECEPTOR CXCR3; CXCL11 CHEMOKINE; CXCL9 CHEMOKINE; CYTARABINE; FLUOROURACIL; GAMMA INTERFERON INDUCIBLE PROTEIN 10; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; S6 KINASE; STAT5 PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BONE MARROW SUPPRESSION; BONE MARROW TOXICITY; CANCER CHEMOTHERAPY; CELL CYCLE; CELL DIFFERENTIATION; CELL EXPANSION; CONTROLLED STUDY; CONVALESCENCE; CYTOTOXICITY; GENE EXPRESSION; HEMATOPOIESIS; HEMATOPOIETIC STEM CELL; IN VITRO STUDY; IN VIVO STUDY; LEUKOCYTE; MESENCHYMAL STROMA CELL; MORTALITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RAT; SURVIVAL RATE;

EID: 84861503829     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2011-07-367581     Document Type: Article

References (49)

1. Moore MA. Review: Stratton Lecture 1990. Clinical implications of positive and negative hematopoietic stem cell regulators. Blood. 1991;78(1):1-19.
2. Han W, Yu Y, Liu XY. Local signals in stem cellbased bone marrow regeneration. Cell Res. 2006;16(2):189-195. (Pubitemid 43247976)
3. Tubiana M, Carde P, Frindel E. Ways of minimising hematopoietic damage induced by radiation and cytostatic drugs-the possible role of inhibitors. Radiother Oncol. 1993;29(1):1-17. (Pubitemid 23336813)
4. Mauch P, Constine L, Greenberger J, et al. Hematopoietic stem cell compartment: acute and late effects of radiation therapy and chemotherapy. Int J Radiat Oncol Biol Phys. 1995;31(5): 1319-1339.
5. Harrison DE, Lerner CP. Most primitive hematopoietic stem cells are stimulated to cycle rapidly after treatment with 5-fluorouracil. Blood. 1991; 78(5):1237-1240.
6. Kopp HG,Avecilla ST, HooperAT, et al. Tie2 activation contributes to hemangiogenic regeneration after myelosuppression. Blood. 2005;106(2):505-513. (Pubitemid 40981244)
7. Broxmeyer HE, Kim CH, Cooper SH, Hangoc G, Hromas R, Pelus LM. Effects of CC, CXC, C, and CX3C chemokines on proliferation of myeloid progenitor cells, and insights into SDF-1-induced chemotaxis of progenitors. Ann N Y Acad Sci. 1999;872:142-162; discussion 163.
8. Gilmore GL, DePasquale DK, Shadduck RK. Protective effects of BB-10010 treatment on chemotherapy- induced neutropenia in mice. Exp Hematol. 1999;27(2):195-202. (Pubitemid 29131728)
9. Keller JR, Bartelmez SH, Sitnicka E, et al. Distinct and overlapping direct effects of macrophage inflammatory protein-1 alpha and transforming growth factor beta on hematopoietic progenitor/ stem cell growth. Blood. 1994;84(7):2175-2181. (Pubitemid 24296375)
10. Clemons MJ, Marshall E, Durig J, et al. A randomized phase-II study of BB-10010 (macrophage inflammatory protein-1alpha) in patients with advanced breast cancer receiving 5-fluorouracil, adriamycin, and cyclophosphamide chemotherapy. Blood. 1998;92(5):1532-1540. (Pubitemid 28406856)
11. Bacon K, Baggiolini M, Broxmeyer H, et al. Chemokine/chemokine receptor nomenclature. J Interferon Cytokine Res. 2002;22(10):1067- 1068.
12. Trotta T, Costantini S, Colonna G. Modelling of the membrane receptor CXCR3 and its complexes with CXCL9, CXCL10 and CXCL11 chemokines: putative target for new drug design. Mol Immunol. 2009;47(2-3):332-339.
13. Colonna M. Toll-like receptors and IFN-alpha: partners in autoimmunity. J Clin Invest. 2006; 116(9):2319-2322. (Pubitemid 44330127)
14. Fall N, Bove KE, Stringer K, et al. Association between lack of angiogenic response in muscle tissue and high expression of angiostatic ELRnegative CXC chemokines in patients with juvenile dermatomyositis: possible link to vasculopathy. Arthritis Rheum. 2005;52(10):3175-3180. (Pubitemid 41447100)
15. Gong JH, Nicholls EF, Elliott MR, et al. G-protein-coupled receptor independent, immunomodulatory properties of chemokine CXCL9. Cell Immunol. 2010;261(2):105-113.
16. Farber JM. HuMig: a new human member of the chemokine family of cytokines. Biochem Biophys Res Commun. 1993;192(1):223-230. (Pubitemid 23205290)
17. Soto H, Wang W, Strieter RM, et al. The CC chemokine 6Ckine binds the CXC chemokine receptor CXCR3. Proc Natl Acad Sci U S A. 1998; 95(14):8205-8210. (Pubitemid 28326091)
18. Lu B, Humbles A, Bota D, et al. Structure and function of the murine chemokine receptor CXCR3. Eur J Immunol. 1999;29(11):3804-3812. (Pubitemid 29527830)
19. Broxmeyer HE, Pelus LM, Kim CH, Hangoc G, Cooper S, Hromas R. Synergistic inhibition in vivo of bone marrow myeloid progenitors by myelosuppressive chemokines and chemokineaccelerated recovery of progenitors after treatment of mice with Ara-C. Exp Hematol. 2006; 34(8):1069-1077. (Pubitemid 44080386)
20. Park MK, Amichay D, Love P, et al. The CXC chemokine murine monokine induced by IFNgamma (CXC chemokine ligand 9) is made by APCs, targets lymphocytes including activated B cells, and supports antibody responses to a bacterial pathogen in vivo. J Immunol. 2002; 169(3):1433-1443. (Pubitemid 34811943)
21. Hancock WW, Lu B, Gao W, et al. Requirement of the chemokine receptor CXCR3 for acute allograft rejection. J Exp Med. 2000;192(10):1515- 1520.
22. Lu H, Yu M, Sun Y, et al. Expression and purification of bioactive high-purity mouse monokine induced by IFN-gamma in Escherichia coli. Protein Expr Purif. 2007;55(1):132-138. (Pubitemid 47259687)
23. Moldenhauer A, Futschik M, Lu H, et al. Interleukin 32 promotes hematopoietic progenitor expansion and attenuates bone marrow cytotoxicity. Eur J Immunol. 2011;41(6):1774-1786.
24. Han W, Ye Q, Moore MA. A soluble form of human Delta-like-1 inhibits differentiation of hematopoietic progenitor cells. Blood. 2000;95(5):1616- 1625.
25. Till JE, McCulloch EA. A direct measurement of the radiation sensitivity of normal mouse bone marrow cells. Radiat Res. 1961;14:213-222.
26. Moldenhauer A, Genter G, Lun A, Bal G, Kiesewetter H, Salama A. Hematopoietic progenitor cells and interleukin-stimulated endothelium: expansion and differentiation of myeloid precursors. BMC Immunol. 2008;9:56.
27. Chamberlain G, Wright K, Rot A, Ashton B, Middleton J. Murine mesenchymal stem cells exhibit a restricted repertoire of functional chemokine receptors: comparison with human. PLoS One. 2008;3(8):e2934.
28. Halfon S, Abramov N, Grinblat B, Ginis I. Markers distinguishing mesenchymal stem cells from fibroblasts are downregulated with passaging. Stem Cells Dev. 2011;20(1):53-66.
29. Le Blanc K, Rasmusson I, Sundberg B, et al. Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells. Lancet. 2004;363(9419):1439-1441. (Pubitemid 38586721)
30. Li T, Wu Y. Paracrine molecules of mesenchymal stem cells for hematopoietic stem cell niche. Bone Marrow Res. 2011;2011:353878.
31. Han L, Wierenga AT, Rozenveld-Geugien M, van de Lande K, Vellenga E, Schuringa JJ. Single-cell STAT5 signal transduction profiling in normal and leukemic stem and progenitor cell populations reveals highly distinct cytokine responses. PLoS One. 2009;4(11):e7989.
32. Liu MT, Armstrong D, Hamilton TA, Lane TE. Expression of Mig (monokine induced by interferongamma) is important in T lymphocyte recruitment and host defense following viral infection of the central nervous system. J Immunol. 2001;166(3): 1790-1795. (Pubitemid 32114664)
33. Yoong KF, Afford SC, Jones R, et al. Expression and function of CXC and CC chemokines in human malignant liver tumors: a role for human monokine induced by gamma-interferon in lymphocyte recruitment to hepatocellular carcinoma. Hepatology. 1999;30(1):100-111. (Pubitemid 29300575)
34. Sauty A, Dziejman M, Taha RA, et al. The T cellspecific CXC chemokines IP-10, Mig, and I-TAC are expressed by activated human bronchial epithelial cells. J Immunol. 1999;162(6):3549-3558. (Pubitemid 29313608)
35. Hardison JL, Wrightsman RA, Carpenter PM, Lane TE, Manning JE. The chemokines CXCL9 and CXCL10 promote a protective immune response but do not contribute to cardiac inflammation following infection with Trypanosoma cruzi. Infect Immun. 2006;74(1):125-134. (Pubitemid 43023066)
36. Kobayashi H, Novick AC, Toma H, Fairchild RL. Chronic antagonism of Mig inhibits cellular infiltration and promotes survival of class II MHC disparate skin allografts. Transplantation. 2002;74(3): 387-395.
37. Romagnani P, Annunziato F, Lasagni L, et al. Cell cycle-dependent expression of CXC chemokine receptor 3 by endothelial cells mediates angiostatic activity. J Clin Invest. 2001;107(1):53-63. (Pubitemid 32047414)
38. Proost P, Schutyser E, Menten P, et al. Aminoterminal truncation of CXCR3 agonists impairs receptor signaling and lymphocyte chemotaxis, while preserving antiangiogenic properties. Blood. 2001;98(13):3554-3561.
39. Shin S, Wolgamott L, Yu Y, Blenis J, Yoon SO. Glycogen synthase kinase (GSK)-3 promotes p70 ribosomal protein S6 kinase (p70S6K) activity and cell proliferation. Proc Natl Acad Sci U S A. 2011;108(47):E1204-E1213.
40. Briaud I, Lingohr MK, Dickson LM, Wrede CE, Rhodes CJ. Differential activation mechanisms of Erk-1/2 and p70(S6K) by glucose in pancreatic beta-cells. Diabetes. 2003;52(4):974-983. (Pubitemid 36388732)
41. Samardzic T, Jankovic V, Stosic-Grujicic S, Trajkovic V. STAT1 is required for iNOS activation, but not IL-6 production in murine fibroblasts. Cytokine. 2001;13(3):179-182. (Pubitemid 32579308)
42. Rosenzweig SD, Holland SM. Defects in the interferon- gamma and interleukin-12 pathways. Immunol Rev. 2005;203:38-47. (Pubitemid 40179692)
43. Kosonen O, Kankaanranta H, Lahde M, Vuorinen P, Ylitalo P, Moilanen E. Nitric oxidereleasing oxatriazole derivatives inhibit human lymphocyte proliferation by a cyclic GMP-independent mechanism. J Pharmacol Exp Ther. 1998;286(1):215-220. (Pubitemid 28317993)
44. Rhodes CJ, White MF. Molecular insights into insulin action and secretion. Eur J Clin Investig. 2002;32(Suppl 3):3-13. (Pubitemid 41704995)
45. Saeki K, Yasugi E, Okuma E, et al. Proteomic analysis on insulin signaling in human hematopoietic cells: identification of CLIC1 and SRp20 as novel downstream effectors of insulin. Am J Physiol Endocrinol Metab. 2005;289(3):E419- E428.
46. Ryu JM, Lee MY, Yun SP, Han HJ. High glucose regulates cyclin D1/E of human mesenchymal stem cells through TGF-beta1 expression via Ca2-/PKC/MAPKs and PI3K/Akt/mTOR signal pathways. J Cell Physiol. 2010;224(1):59-70.
47. Cheng T, Shen H, Rodrigues N, Stier S, Scadden DT. Transforming growth factor beta 1 mediates cell-cycle arrest of primitive hematopoietic cells independent of p21(Cip1/Waf1) or p27(Kip1). Blood. 2001;98(13):3643-3649.
48. Schepers H, van Gosliga D, Wierenga AT, Eggen BJ, Schuringa JJ, Vellenga E. STAT5 is required for long-term maintenance of normal and leukemic human stem/progenitor cells. Blood. 2007;110(8):2880-2888. (Pubitemid 350006941)
49. Furuya M, Yoneyama T, Miyagi E, et al. Differential expression patterns of CXCR3 variants and corresponding CXC chemokines in clear cell ovarian cancers and endometriosis. Gynecol Oncol. 2011;122(3):648-655.